Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 7/2014

01-07-2014 | Original Research Paper

Forsythin inhibits lipopolysaccharide-induced inflammation by suppressing JAK-STAT and p38 MAPK signalings and ROS production

Authors: Xiaolong Pan, Xiang Cao, Na Li, Yimiao Xu, Qiuyue Wu, Jing Bai, Zhimin Yin, Lan Luo, Lei Lan

Published in: Inflammation Research | Issue 7/2014

Login to get access

Abstract

Objective

Forsythin (FOR) is an active ingredient extracted from the fruit of the medicinal plant Forsythia suspensa (Thunb.) Vahl. Here, we investigated the effect of FOR on LPS-induced inflammatory response and the underlying molecular mechanisms in RAW264.7 macrophages.

Materials and methods

RAW264.7 cells were pre-treated with or without FOR and then stimulated with or without LPS. The productions of TNF-α, IL-1β, IL-6, PGE2 and NO were determined by ELISA and nitrite analysis, respectively. The expressions of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were measured by Western blotting and RT-PCR analysis. The activations of signaling molecules were detected by Western blotting using phosphorylation specific antibodies. Reactive oxygen species (ROS) production was determined by ROS assay.

Results

LPS-induced productions of IL-1β, IL-6, TNF-α, NO and PGE2 were inhibited by FOR in a dose-dependent manner. FOR also suppressed the LPS-elevated expressions of iNOS and COX-2. Further investigations revealed that FOR significantly inhibited the LPS-induced activations of JAK-STATs and p38 MAPKs, but not of IKKα/β in LPS-stimulated RAW264.7 cells. Additionally, FOR interfered with both JAK-STATs and p38 MAPKs signaling pathways to modulate the expressions of IL-1β, IL-6, TNF-α, iNOS and COX-2. Furthermore, FOR reduced the LPS-induced ROS accumulation, validating that FOR serves as an antioxidant.

Conclusions

Our data suggested that FOR exerts anti-inflammatory action, at least in part, via suppressing LPS-induced activation of JAK-STATs and p38 MAPKs signalings and production of ROS in macrophage cells.
Appendix
Available only for authorised users
Literature
1.
Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA. 1995;273(2):117–23.PubMedCrossRef
2.
Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 1994;8(2):217–25.PubMed
3.
ter Steege JC, van de Ven MW, Forget PP, Brouckaert P, Buurman WA. The role of endogenous IFN-γ, TNF-α and IL-10 in LPS-induced nitric oxide release in a mouse model. Cytokine. 1998;10(2):115–23.PubMedCrossRef
4.
Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol. 2002;2(10):787–95.PubMedCrossRef
5.
6.
7.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.PubMedCrossRef
8.
9.
Coker R, Laurent G. Pulmonary fibrosis: cytokines in the balance. Eur Respir J. 1998;11(6):1218–21.PubMedCrossRef
10.
Liou H-C. Regulation of the immune system by NF-kappaB and IkappaB. J Biochem Mol Biol. 2002;35(6):537–46.PubMedCrossRef
11.
Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000;12(1):85–98.PubMedCrossRef
12.
13.
Kisseleva T, Bhattacharya S, Braunstein J, Schindler C. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1):1–24.PubMedCrossRef
14.
Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, Zotter A, et al. Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J. 2001;20(1):91–100.PubMedCentralPubMedCrossRef
15.
Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Statl and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82(2):241–50.PubMedCrossRef
16.
Chan ED, Riches DW. IFN-γ + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38 mapk in a mouse macrophage cell line. Am J Physiol Cell Physiol. 2001;280(3):441–50.
17.
Chen B, Chen Y, Lin W. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology. 1999;97(1):124–9.PubMedCentralPubMedCrossRef
18.
Li H-B, Chen F. Preparative isolation and purification of phillyrin from the medicinal plant Forsythia suspensa by high-speed counter-current chromatography. J Chromatogr A. 2005;1083(1):102–5.PubMedCrossRef
19.
Cuéllar M, Giner R, Recio M, Just M, Máñez S, Cerda S, et al. Screening of antiinflammatory medicinal plants used in traditional medicine against skin diseases. Phytother Res. 1998;12(1):18–23.CrossRef
20.
Schinella G, Tournier H, Prieto J, De Buschiazzo PM, Rıos J. Antioxidant activity of anti-inflammatory plant extracts. Life Sci. 2002;70(9):1023–33.PubMedCrossRef
21.
Chen H-Y, Shiao M-S, Huang Y-L, Shen C-C, Lin Y-L, Kuo Y-H, et al. Antioxidant principles from ephemerantha l onchophylla. J Nat Prod. 1999;62(9):1225–7.PubMedCrossRef
22.
Ozaki Y, Rui J, Tang Y, Satake M. Antiinflammatory effect of Forsythia suspensa Vahl and its active fraction. Biol Pharma Bull. 1997;20(8):861.CrossRef
23.
Qu H, Zhang Y, Wang Y, Li B, Sun W. Antioxidant and antibacterial activity of two compounds (forsythiaside and forsythin) isolated from Forsythia suspensa. J Pharm Pharmacol. 2008;60(2):261–6.PubMedCrossRef
24.
Cao X, Yue L, Song J, Wu Q, Li N, Luo L, et al. Inducible HSP70 antagonizes IL-1β cytocidal effects through inhibiting NF-kB activation via destabilizing TAK1 in HeLa cells. PLoS One. 2012;7(11):e50059.PubMedCentralPubMedCrossRef
25.
Hoffmann A, Baltimore D. Circuitry of nuclear factor κB signaling. Immunol Rev. 2006;210(1):171–86.PubMedCrossRef
26.
Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–9.PubMedCrossRef
27.
Pfitzner E, Kliem S, Baus D, Litterst M. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des. 2004;10(23):2839–50.PubMedCrossRef
28.
Levy DE, Darnell J. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–62.PubMedCrossRef
29.
Qi Z, Yin F, Lu L, Shen L, Qi S, Lan L, et al. Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production. Inflamm Res. 2013;62(9):845–55.CrossRef
30.
Carter AB, Monick MM, Hunninghake GW. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol. 1999;20(4):751–8.PubMedCrossRef
31.
Lee JC, Young PR. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol. 1996;59(2):152–7.PubMed
32.
Qi S, Xin Y, Guo Y, Diao Y, Kou X, Luo L, et al. Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3 K/Akt/NF-κB signaling pathways. Int Immunopharmacol. 2012;12(1):278–87.PubMedCrossRef
33.
34.
Aruoma OI, Grootveld M, Bahorun T. Free radicals in biology and medicine: from inflammation to biotechnology. Biofactors. 2006;27(1–4):1–3.PubMedCrossRef
35.
Qu H, Zhang Y, Chai X, Sun W. Isoforsythiaside, an antioxidant and antibacterial phenylethanoid glycoside isolated from Forsythia suspensa. Bioorg Chem. 2012;40:87–91.PubMedCrossRef
36.
JiuLin H, ChunYan W, QingHua L. Study on the content of forsythin, total flavonoids of Forsythia suspensa and their antioxidant activity. Med Plant. 2012;3(6):28–30.
37.
Liu Z, Fan Y, Wang Y, Han C, Pan Y, Huang H, et al. Dipyrithione inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in macrophages and protects against endotoxic shock in mice. FEBS Lett. 2008;582(12):1643–50.PubMedCrossRef
38.
Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006;38(10):1654–61.PubMedCrossRef
39.
Okugawa S, Ota Y, Kitazawa T, Nakayama K, Yanagimoto S, Tsukada K, et al. Janus kinase 2 is involved in lipopolysaccharide-induced activation of macrophages. Am J Physiol Cell Physiol. 2003;285(2):399–408.CrossRef
40.
Park EJ, Park SY, Joe E-h, Jou I. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem. 2003;278(17):14747–52.PubMedCrossRef
41.
Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M, et al. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-γ uses a different signaling pathway. Proc Natl Acad Sci. 1999;96(24):13956–61.PubMedCentralPubMedCrossRef
42.
Shuai K, Liu B. Regulation of JAK–STAT signalling in the immune system. Nat Rev Immunol. 2003;3(11):900–11.PubMedCrossRef
43.
Galdiero M, Vitiello M, D’Isanto M, Raieta K, Galdiero E. STAT1 and STAT3 phosphorylation by porins are independent of JAKs but are dependent on MAPK pathway and plays a role in U937 cells production of interleukin-6. Cytokine. 2006;36(5):218–28.PubMedCrossRef
44.
Sakaguchi M, Oka M, Iwasaki T, Fukami Y, Nishigori C. Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells. J Investig Dermatol. 2012;132(7):1877–85.PubMedCrossRef
45.
Choi J-S, Choi Y-J, Shin S-Y, Li J, Kang S-W, Bae J-Y, et al. Dietary flavonoids differentially reduce oxidized LDL-induced apoptosis in human endothelial cells: role of MAPK-and JAK/STAT-signaling. J Nutr. 2008;138(6):983–90.PubMed
46.
Simon AR, Rai U, Fanburg BL, Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol Cell Physiol. 1998;275(6):1640–52.
47.
Ohmori Y, Hamilton TA. Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol. 2001;69(4):598–604.PubMed
Metadata
Title
Forsythin inhibits lipopolysaccharide-induced inflammation by suppressing JAK-STAT and p38 MAPK signalings and ROS production
Authors
Xiaolong Pan
Xiang Cao
Na Li
Yimiao Xu
Qiuyue Wu
Jing Bai
Zhimin Yin
Lan Luo
Lei Lan
Publication date
01-07-2014
Publisher
Springer Basel
Published in
Inflammation Research / Issue 7/2014
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-014-0731-7

Other articles of this Issue 7/2014

Inflammation Research 7/2014 Go to the issue

Original Research Paper

The alpha 7 nicotinic receptor agonist PHA-543613 hydrochloride inhibits Porphyromonas gingivalis-induced expression of interleukin-8 by oral keratinocytes

Review

Role of Interleukin-22 in liver diseases

Original Research Paper

Rapid shedding of proinflammatory microparticles by human mononuclear cells exposed to cigarette smoke is dependent on Ca2+ mobilization

Original Research Paper

Sulfated polysaccharides isolated from the green seaweed Caulerpa racemosa plays antinociceptive and anti-inflammatory activities in a way dependent on HO-1 pathway activation

Original Research Paper

Protein kinase C-δ mediates sepsis-induced activation of complement 5a and urokinase-type plasminogen activator signaling in macrophages

Original Research Paper

Genetic polymorphism of CCL2−2518, CXCL10−201, IL8+781 and susceptibility to severity of Enterovirus-71 infection in a Chinese population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits